inhibition of a human squamous cell carcinoma of the head and neck in nude mice: Dependency on the route of administration. Int J Oncol 24:227-232

[0288] 18. McLaughlin P J, Stack B C, Levin R J, Fedok F., Zagon I S (2003) Defects in the OGF receptor (OGFr) in human squamous cell carcinoma of the head and neck. Cancer 97:1701-1710

[0289] 19. Parkin D M, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49:33-64

[0290] 20. Schantz S, Harrison L B, Forastiere A A (1997) Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: DeVita V T, Hellman S, Rosenberg S A (eds) Cancer Principles and Practice of Oncology 5th edition pp. 741-801. Lippincott-Raven Philadelphia:

[0291] 21. Schiff P B, Fant J, Horwitz S B (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667

[0292] 22. Schiff P B, Horwitz S B (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77:1561-1565

[0293] 23. Shah J P, Lydiatt W (1995) Treatment of cancer of the head and neck. C A-Cancer J Clin 45:352-368

[0294] 24. Shim W S N, Teh M, Mack P O P, Ge R (2001) Inhibition of angiopoietin-1 expression in tumor cells by an antisense RNA approach inhibited xenograft tumor growth in immunodeficient mice. Int J Cancer 94:6-15

[0295] 25. Shin D M, Khuri F R, Glisson B S, Ginsberg L, Papadimitrakopoulou V M, Clayman G., Lee J J, Ang K K, Lippman S M, Hong W K (2001) Phase I I study of paclitaxel, ifosafamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 91:1316-1323

[0296] 26. Smith J P, Conter R L, Bingaman S I, Harvey H A, Mauger D T, Ahmad M, Demers L M, Stanley W B, McLaughlin P J, Zagon I S (2004) Treatment of advanced pancreatic cancer with opioid growth factor: Phase I. Anti-Cancer Drugs 15:203-209

[0297] 27. Srivastava R K, Srivastava A R, Korsmeyer S J, Nesterova M, Cho-Chung Y S, Longo D L (1998) Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 18:3509-3517

[0298] 28. Villena-Heinsen C, Friedrich M, Ertan A K, Farnhammer C, Schmidt W (1998) Human ovarian cancer xenografts in nude mice: Chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride. Anticancer Drugs 9:557-563

[0299] 29. Vokes E E, Haraf D J, Stenson K, Stupp R, Malone D, Levin J, Weichselbaum R R (1995) The role of paclitaxel in the treatment of head and neck cancer. Sem Oncol 22:8-12

[0300] 30. Wilson R P, McLaughlin P J, Lang C M, Zagon I S (2000) The opioid growth factor, [Met^5]-enkephalin, inhibits DNA synthesis during recornification of mouse tail skin. Cell Proliferation 33:63-73

[0301] 31. Zagon I S, McLaughlin P J (2003) Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 37:79-88

[0302] 32. Zagon I S, Roesener C D, Verderame M F, Ohlsson-Wilhelm B M, Levin R J, McLaughlin P J (2000) Opioid growth factor regulates the cell cycle of human neoplasias. Int J Oncol 17:1053-1061

[0303] 33. Zagon I S, Verderame M F, Allen S S, McLaughlin P J (2000) Cloning, sequencing, chromosomal location, and function of a cDNA encoding the opioid growth factor receptor (OGFr) in humans. Brain Res 856:75-83

[0304] 34. Zagon I S, Wu Y, McLaughlin P J (1994) Opioid growth factor (OGF) inhibits DNA synthesis in mouse tongue epithelium in a circadian-rhythm-dependent manner. Am J Physiol 267:R645-R652

[0305] 35. Zagon I S, Wu Y, McLaughlin P J (1999) Opioid growth factor and organ development in rat and human embryos. Brain Res 839:313-322

TABLE 8

Incidence and latency for tumor appearance of SCC-1 squamous cell carcinoma cells in nude mice treated with OGF and/or paclitaxel.

Parameter	Control	OGF	Paclitaxel	Paclitaxel/ OGF
N	12	12	12	10
Incidence of measurable tumor (day 13)	9/12	4/12[a]	8/12	7/10
Incidence of measurable tumor (day 17)	12/12	8/12	10/12	9/10
Latency to visible tumor (days)	7.2 ± 0.5	11.2 ± 1.5[b]	7.4 ± 1.4	8.6 ± 0.8
Latency to measurable tumor (days)	14.2 ± 0.6	17.0 ± 1.5	14.8 ± 1.7	15.5 ± 1.5

Values represent means ± SEM.
[a]Significantly different from the control group by Chi-square analyses at $p < 0.05$.
[b]Significantly different at $p < 0.02$ from controls using ANOVA.

TABLE 9

Characteristics of nude mice 50 days after subcutaneous inoculation of SCC-1 squamous carcinoma cells and treatment (i.p.) with OGF and/or paclitaxel

Parameter	Controls	OGF	Paclitaxel	Paclitaxel/ OGF
Body Weight, g	31.6 ± 0.7	32.0 ± 0.5	22.6 ± 0.8***+++^^^	31.8 ± 1.1
Tumor Weight, g	2.4 ± 0.2	1.7 ± 0.2**	N.A.	0.9 ± 0.7***+++
Tumor Volume, mm^3	3896 ± 535	590 ± 364*	N.A.	1223 ± 238***+